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Inflammatory cytokines are important predictors of
cardiovascular mortality especially in patients with chronic
kidney disease. Here we explored the relationship of anemia
and epoetin treatment to inflammatory cytokine levels
in patients with chronic kidney disease. One hundred
non-dialysis patients with chronic kidney disease over
18 years of age were evenly split into anemic and
non-anemic cohorts. Of the 50 anemic patients, 23 were
receiving erythropoiesis stimulating agents treatments.
Levels of tumor necrosis factor (TNF)-a were found to be
significantly higher and serum albumin was significantly
lower with trends towards higher interleukin (IL)-6 and IL-8 in
anemic compared to non-anemic patients. Further analysis
by multiple logistic regression found that anemic patients
treated with erythropoiesis stimulating agents had
significantly higher odds for the upper two quartiles for
IL-6, IL-8 and TNF-a compared to non-anemic patients.
Our study found that the anemia of chronic kidney disease
was associated with up regulation of TNF-a, and possibly
IL-6 and IL-8 along with increased levels of these
proinflammatory cytokines in patients treated with epoetin.
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Cardiovascular disease (CVD) remains the principal cause
of mortality in patients with chronic kidney disease (CKD).
The association of anemia with cardiovascular outcomes is
well known, but underlying mechanisms are not well
understood.1 On the other hand, targeting of a higher
hemoglobin with higher doses of erythropoiesis-stimulating
agents (ESAs) worsens cardiovascular outcomes in CKD.2,3
The reason for higher mortality in patients targeted for the
higher hemoglobin is an area of intense research. Possibilities
include a heightened prothrombotic tendency because
of higher hemoglobin levels or a potentially toxic effect of
ESAs on the cardiovascular system.4 The potential influence
of inflammation in CKD patients with anemia on ESAs
treatment is not well understood.
Evidence supports a role for inflammation in athero-
sclerosis.5,6 Inflammation has also been shown to play a
role in atherosclerosis in all stages of CKD.7 Some of the
biomarkers studied in relation to inflammation in CKD
include interleukin (IL)-1b, IL-6, IL-8, tumor necrosis factor
(TNF)-a, and C-reactive protein.8,9 Elevated levels of these
markers are detectable even among patients without evidence
of clinical or sub-clinical CVD. Thus, inflammation presents
as an early phenomenon among CKD patients and might
play a role in promoting atherosclerosis. These mechanisms
may, in part, explain the high incidence of cardiovascular
events in CKD patients and the high prevalence of CVD in
end-stage renal disease patients.
We hypothesized that exposure to ESA therapy may result
in proinflammatory cytokine activation. Consequently, in
this study, we evaluated the levels of several bio-inflamma-
tory markers in CKD patients with and without anemia who
were either treated with ESA therapy or were ESA-naive.
RESULTS
Patient characteristics by CKD-associated anemia
The baseline characteristic of the CKD cohort is presented
in Table 1. Anemia was defined by modified World Health
Organization (WHO) criteria as less than 12 g/dl in women
and less than 13 g/dl in men or treatment with ESAs. Of
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the 100 patients analyzed, 50 patients were anemic by the
modified WHO criteria. The mean Hgb level in anemic
patients was 11.2 g/dl and in non-anemic patients was
13.8 g/dl. Anemic patients tended to be predominantly male
and significantly older by age, with a mean age of 64 years.
These patients also had a significantly reduced estimated
glomerular filtration rate (eGFR) calculated using the
Modification of Diet in Renal Disease II equation and were
predominantly in stage 3 and stage 4 CKD (eGFR 15–60 ml/
min per 1.73 m2). Non-anemic patients were predo-
minantly in stage 2 and stage 3 CKD (eGFR 30–90 ml/min
per 1.73 m2). No other significant differences were observed.
In all, 23% (N¼ 23) of patients were treated with ESAs;
of ESA-treated patients, 57% (N¼ 13) were on epoetin-a
(median dose of 10,000 U/week) and 43% (N¼ 10) on
darbepoetin.
Proinflammatory markers and anemia
A non-parametric test was used for comparison as the
data were not normally distributed. For anemic (by modified
WHO classification) vs non-anemic patients, the median
(interquartile range) levels for IL-6 were 4.65 pg/ml (0.64,
12.38) and 1.09 pg/ml (0.64, 8.34) (P¼ 0.12), respectively; for
IL-8 were 7.85 pg/ml (2.64, 13.17) vs 3.66 pg/ml (1.37, 10.15)
(P¼ 0.05), respectively; and for TNF-a were 4.54 pg/ml (1.89,
7.18) vs 2.36 pg/ml (1.10, 4.54) (P¼ 0.019), respectively.
Notably, serum albumin levels were 4.1 g/100 ml (3.90, 4.30)
and 4.40 g/100 ml (4.07, 4.52) (Po0.002) for anemic and
non-anemic patients respectively, whereas the serum ferritin
levels were not different: 96 ng/ml (52, 282) and 93 ng/ml
(53, 151) (P¼ 0.56) in anemic and non-anemic subjects
respectively.
As there are different classifications for anemia and defini-
tions may be viewed as relatively arbitrary, we performed
four sensitivity analyses for different hemoglobin levels
(Table 2). The first sensitivity analysis was performed by
strictly classifying subjects based on the WHO criteria with or
without including treatment with ESAs as a cause of anemia
(WHO definition of anemia is p13 g/dl for adult male and
p12 g/dl an adult female): 48 patients were classified as
Table 1 | Baseline characteristics of CKD patients stratified by anemic statusa
Characteristic Anemic CKD patients (N=50) Non-anemic CKD patients (N=50) P-value
Age in years 64.2±14.8 53.6±17.2 0.002*
Gender (M/F) 64:36 32:68 0.001*
Race 0.73
White 56.0 54
Black 28 20
Hispanic 10 18
Asian 4 6
Others 2.0 2
Etiology of CKDb 0.43
Diabetic nephropathy 38 24
Hypertension 24 20
Chronic glomerulonephritis 12 24
Chronic interstitial nephritis 10 8
Lupus nephritis 12 16
Others 4 8
Diabetes 38 30 0.26
Hypertension 86 72 0.07
History of smoking 8.2 7 0.23
Serum creatinine (mg/dl) 2.7±1.5 1.7±1.0 o0.001*
MDRD GFR (ml/min per 1.73 m2)c 31.4±19.6 53.8±31.6 o0.001*
Platelets 275.8±64.6 231.7±94.8 0.008*
Hemoglobin (g/dl) 11.2±1.2 13.8±1.1 o0.001*
TSAT in % 23.9±9.5 28.1±13.3 0.08
Random blood sugar (mg/dl) 105.4±47.3 100.3±33.0 0.54
Mean duration of ESAs (in months) 6.8±12.4
(N=23)
—
Median dose of ESAs (U/kg)d 8000 (N=23) —
CKD, chronic kidney disease; ESAs, erythropoiesis-stimulating agents; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
All continuous data expressed as mean±s.d.
Categorical data expressed in percentages.
*Significant if P-value is o0.05.
TSAT refers to percentage of transferrin saturation.
aModified WHO classification of anemia is used where anemia is defined as presence of Hgbo12 g/100 ml in women or Hgbo13 g/100 ml in men on treatment with ESAs.
bCKD defined as GFRo60 ml/min per 1.73 m2 or GFRX60 ml/min per 1.73 m2 with albuminuria.
cMDRD GFR refers to glomerular filtration rate equation measured by modification of diet in renal disease formula type II: eGFR (ml/min per 1.73 m2)=186
[Cr (mg/100 ml)]1.154 (age)0.203 (1.21 if subject is black).
dOf ESA-treated patients, 57% (N=13) were on epoetin-a (median dose of 10, 000 U/week) and 43% (N=10) on darbepoetin (median dose of 7000 U/week; a conversion of
300 U for each microgram of darbepoetin-a was done).
Kidney International (2008) 74, 782–790 783
SR Keithi-Reddy et al.: Anemia, ESAs and inflammation o r i g i n a l a r t i c l e
anemic. The levels of IL-8 (P¼ 0.0013) and TNF-a (0.016)
were significantly higher but there was no difference for IL-6
(P¼ 0.11), whereas serum albumin levels were significantly
lower (Po0.001) in patients with anemia. However, the
levels of serum ferritin were not different in these groups.
The second sensitivity analysis was performed based on
the National Kidney Foundation criteria for anemia (anemia
is o13.5 g/dl for an adult male and o12 g/dl for an adult
female): 54 patients were classified as anemic. The level
of TNF-a (P¼ 0.049) was significantly higher and serum
albumin levels significantly lower (P¼ 0.005) in these
patients with National Kidney Foundation-defined anemia.
There was no significant difference in IL-6 and IL-8 levels and
serum ferritin levels. In the third and fourth sensitivity
analyses, we used lower hemoglobin values to describe
anemia, defining CKD anemia for both males and females
as p12 and p11 g/dl, respectively. The level of TNF-a
remained significantly elevated in CKD anemic patients,
and IL-6 and IL-8 levels were not significantly different in
anemic subjects.
We evaluated C-reactive protein (CRP) levels in CKD
patients with and without anemia (N¼ 74). CRP levels were
divided into tertiles. Tertiles for CRP was based on the
distribution of CRP in the sample, as the cut points are less
well defined, consistent with the previous literature.10 The
median (interquartile range) levels for CRP were 1.60 mg/l
(0.60, 4.32) in anemic patients and 1.19 mg/l (0.46, 3.42).
Among anemic subjects, 35.9% were in the third tertile
whereas 33% were in the first tertile for CRP (Mantel–-
Haenszel test for linear association; P¼ 0.58). Thus, CRP
trends were not significantly affected by the presence of
anemia in our CKD cohort (Figure 1a).
We also evaluated IL-10, an important anti-inflammatory
cytokine that limits inflammation and is related to IL-6,
TNF-a, and CRP. IL-10 levels were 4.14 pg/ml (1.80, 8.68) in
anemic patients and 2.88 pg/ml (1.11, 5.86) in non-anemic
patients (P¼ 0.13).
We observed an inverse relationship between hemoglobin
levels and inflammatory markers such as IL-8 (Spearman’s
correlation coefficient (rs)¼0.28; P¼ 0.004), TNF-a
(rs¼0.32; Po0.001), IL-6 (rs¼0.17; P¼ 0.09), and
CRP levels (rs¼0.19; P¼ 0.09) and positive correlation
between Hgb levels and serum albumin levels (rs¼ 0.35;
Po0.001). In contrast, although there was a significant
inverse correlation between GFR and TNF-a (rs¼0.34;
Table 2 | Inflammatory markers by anemic status: sensitivity analysis
Markera
P-value by Mod.
WHO criteriab
P-value by WHO
criteriac
P-value by NKF
criteriad
P-value for the cut point
Hgbo12 g/dl
P-value for the cut point
Hgbo11 g/dl
Anemic (N=50) Anemic (N=48) Anemic (N=54) Anemic (N=38) Anemic (N=15)
IL-6 0.12 0.11 0.28 0.39 0.52
IL-8 0.05 0.013* 0.07 0.05 0.07
TNF-a 0.019* 0.016* 0.049* 0.016* 0.008*
Serum ferritin 0.56 0.39 0.58 0.69 0.41
Serum albumin 0.002* o0.001* 0.005* 0.001* 0.32
ESAs, erythropoiesis-stimulating agents; IL, interleukin.
Mann–Whitney U test was done for the analysis with levels of inflammatory markers as dependent variables.
*Significant.
aIL-1b was not significantly elevated in both the groups. All the groups had values o0.64 pg/ml.
bModified WHO definition of anemia is used here where anemia is defined as presence of Hgbo12 g/dl in women or Hgbo13 g/dl in men or treatment with ESAs.
cWHO definition of anemia: Hgbo13 g/dl for adult male and o12 g/dl for an adult female.
dNKF definition of anemia: Hgbo13.5 g/dl for adult male and o12 g/dl for an adult female.
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Figure 1 | Number of anemic patients and patients on ESAs by
tertiles of CRP in CKD cohort. Among anemic subjects, 35.9%
were in the third tertile whereas 33% were in the first tertile for
CRP (Mantel–Haenszel test for linear association; P¼ 0.58) (a). Fifty
percentage of the anemic subjects on ESAs were in the third
tertile whereas 33% of epo-naive patients were in the third tertile
for CRP (Mantel–Haenszel test for linear association; P¼ 0.013).
Patients in the first and third tertiles were compared for P-value
(b). CKD, chronic kidney disease; CRP, C-reactive protein; ESAs,
erythropoiesis-stimulating agents.
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Po0.001), other inflammatory marker such as IL-8 (rs¼
0.13; P¼ 0.20), IL-6 (rs¼0.003; P¼ 0.97), CRP (rs¼0.15;
P¼ 0.19), and serum albumin (rs¼0.02; P¼ 0.83) did not
demonstrate any correlation with GFR.
Proinflammatory markers and therapy with ESAs
We examined the potential effect of ESA therapy on
proinflammatory markers. The median levels of inflamma-
tory markers in patients on ESAs and ESA-naive patients
were 6.86 pg/ml (0.64, 16.8) and 2.24 pg/ml (0.64, 7.73) for
IL-6; 9.35 pg/ml (4.86, 13.7) and 7.83 pg/ml (2.36, 12.98)
for IL-8; 4.99 pg/ml (1.95, 7.23) and 3.20 pg/ml (1.87, 6.74)
for TNF-a; 4.20 pg/ml (3.90, 4.40) and 4.10 pg/ml (3.90,
4.20) for serum albumin; and 109.5 pg/ml (52, 354.0) and
90 pg/ml (51, 227) for serum ferritin levels, respectively. The
markers were divided into quartiles, and the odds ratio (OR)
for patients on ESA having an inflammatory biomarker in the
upper two quartiles were compared with ESA-naive and non-
anemic patients (Figure 2). In all, 71.4% of the patients on
ESAs were in upper two quartiles for IL-6 compared to 51.9%
of ESA-naive anemic and 40.4% of non-anemic patients with
unadjusted OR of 3.6 (95% confidence interval (CI),
1.2–11.0; P¼ 0.02). Likewise, 76.2% of the patients on ESAs
were in the upper two quartiles of IL-8 compared to 59.3% of
ESA-naive anemic and 34.6% of non-anemic patients with
unadjusted OR of 6.0 (95% CI, 1.9–19.1; P¼ 0.002). A total
of 71.4% of the patients on ESAs were in upper two quartiles
for TNF-a compared to 55.6% of ESA-naive anemic and
38.5% of non-anemic patients with unadjusted OR of 4.0
(95% CI, 1.3–12.0; P¼ 0.01). However, ferritin was not
significantly different with 60% of the patients on ESAs
in upper two quartiles for ferritin compared to 44% of
ESA-naive anemic and 48.9% of non-anemic patients with
unadjusted OR of 1.5 (95% CI, 0.5–4.5; P¼ 0.40). A total of
61.9% of the patients on ESAs were in the lower two quartiles
for albumin compared to 77.8% of ESA-naive anemic and
34.6% of non-anemic patients. It is worth noting that the
ESA-naive patients had higher OR at 6.0 (95% CI, 1.0–8.7;
P¼ 0.001) compared to patients on ESAs whose unadjusted
OR was 3.0 (95% CI, 1.0–8.7; P¼ 0.03) for serum albumin.
As described above, CRP levels were classified into tertiles.
The analysis revealed that 50% of the patients on ESAs were
in the upper tertile of CRP, compared to 33% of patients who
were ESA-naive (P¼ 0.013 by the Mantel–Haenszel’s linear by
linear association method), and the unadjusted OR of patient
on ESA having the highest tertile of CRP levels was 4.0
(Figure 1b). The median CRP levels in anemic subjects and
non-anemic subjects were 1.71 and 1.18 mg/l, respectively.
The median level of CRP in patients who were ESA-treated vs
patients who were ESA-naive was 2.65 and 0.98 mg/l,
respectively.
We performed analyses of anemic subjects who were
either treated with ESA or were ESA-naive to explore whether
there were differences in IL-10 levels; our data revealed
no significant difference in IL-10 levels. The median IL-10
levels in anemic (by modified WHO classification) and
non-anemic subjects were 4.14 and 2.88 pg/ml, respectively
(P¼ 0.13). The median levels of IL-10 in ESA-treated and
ESA-naive patients were similar at 4.14 pg/ml (P¼ 0.66).
Among the patients treated with ESAs, the duration or
the dose of ESA therapy did not correlate with any of the
inflammatory markers.
Determinants of elevated levels of inflammatory markers
By the Spearman’s rank correlation test, IL-8 levels positively
correlated with IL-6 (rs¼ 0.63; Po0.001) and TNF-a levels
(rs¼ 0.51; Po0.001). In light of a close correlation between
these markers, a composite of upper two quartiles of a
combination of IL-6, IL-8 and TNF-a was considered
as composite outcome variable for multivariate logistic
regression. Anemic patients not on ESAs had modest OR of
reaching the composite outcome variable that did not achieve
statistical significance (OR 1.8 (0.57–5.8); P¼ 0.30). Patients
on ESAs had a higher OR of having the composite outcome
variable (OR 9.1 (95% CI, 1.12–75.3); P¼ 0.03) after we
adjusted for age, gender, GFR, hemoglobin, presence of
diabetes, hypertension, and other inflammatory markers such
as albumin, ferritin, and platelets (Table 3). We also used
other composite outcome variables in sensitivity analyses.
When a composite of third tertile of IL-6, IL-8, and TNF-a
was used as an outcome variable, use of ESAs was associated
with an unadjusted OR of 3.4 (95% CI, 1.1–10.1; P¼ 0.02)
and an adjusted OR of 3.6 (95% CI, 1.1–11.9; P¼ 0.03); when
a composite of upper quartile of IL-6, IL-8, and TNF-a was
used as an outcome variable, unadjusted OR was 3.0 (95%
CI, 1.0–8.7; P¼ 0.03) and adjusted OR was 3.1 (95% CI,
1.0–9.4; P¼ 0.03) for the association with ESA therapy.
DISCUSSION
In this study, we explored the inter-relationships between
anemia, ESA treatment, and markers of inflammation in
CKD patients. We observed that the TNF-a level was higher
and the levels of serum albumin lower in anemic compared
to non-anemic subjects. The directionality of these findings
persisted when sensitivity analyses were performed for
various classifications of anemia. The levels of IL-6, IL-8,
IL-1b, CRP, and serum ferritin did not differ, although there
were trends for increased IL-6 and IL-8, between anemic and
non-anemic patients suggesting that heightened TNF-a level
was unlikely to be explained by a generalized and heightened
state of inflammation attributable to renal dysfunction.
Indeed, these cytokines showed stronger inverse correlation
with hemoglobin than GFR. Analysis of anemic patients
treated with ESA compared to ESA-naive patients revealed
increased OR for IL-6, IL-8, CRP, and TNF-a with ESA
treatment. On multiple logistic regression analysis, ESA-
treated anemic patients had a strong association for the
composite outcome variable of having the upper two
quartiles of IL-6, IL-8, and TNF-a with a multivariate OR
of 9.1.
TNF-a was significantly higher and arguably there was a
trend for higher IL-6 and IL-8 levels in our anemic compared
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to non-anemic subjects with CKD. These cytokines have been
implicated as non-traditional CVD risk factors associated
with an increased risk of atherosclerosis.11 Indeed, IL-6 and
TNF-a stimulate liver production of CRP. Highly sensitive
CRP is clinically used to identify asymptomatic individuals at
risk of coronary events.12,13 IL-8 is a potent angiogenic factor
that induces migration and proliferation of endothelial cells
and smooth muscle cells contributing to plaque formation in
atherosclerosis.14 IL-10 mediates several anti-atherogenic
pathways.15 Furthermore, these cytokines are collectively
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Figure 2 | Odds ratios for upper two quartiles for patients treated with ESAs. In all, 71.4% of the patients on ESAs were in upper
two quartiles for IL-6 compared to 51.9% of ESA-naive anemic and 40.4% of non-anemic patients with unadjusted odds of 3.6 (a). In all,
76.2% of the patients on ESAs were in upper two quartiles for IL-8 compared to 59.3% of ESA-naive anemic and 34.6% of non-anemic
patients with unadjusted odds of 6.0 (b). In total, 71.4% of the patients on ESAs were in upper two quartiles for TNF-a compared to 55.6% of
ESA-naive anemic and 38.5% of non-anemic patients with unadjusted odds of 4.0 (c). Sixty percentage of the patients on ESAs were in the
upper two quartiles for Ferritin compared to 44% of ESA-naive anemic and 48.9% of non-anemic patients with unadjusted odds of 1.5 (d).
A total of 61.9% of the patients on ESAs were in the lower two quartiles for albumin compared to 77.8% of ESA-naive anemic and 34.6%
of non-anemic patients with unadjusted odds of 6.0 (e). Odds ratios are for the use of ESAs. *Lower two and upper two quartiles are
represented in reverse order for the convenience of readers. ESAs, erythropoiesis-stimulating agents; IL, interleukin; TNF-a, tumor
necrosis factor-a.
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considered powerful predictors of carotid atherosclerotic
burden and all-cause cardiovascular mortality in both CKD
and non-CKD subjects.16–18 Among these markers, in studies
of CKD patients, CRP, IL-6, and serum albumin have been
demonstrated to have a strong association with cardiovas-
cular mortality.19,20 Other markers of inflammation in CKD
including IL-8, TNF-a, and IL-10 have shown either subtle or
equivocal association with CVD. It is well known that in CKD
patients, inflammation forms a complex with malnutrition
and atherosclerosis and portends a poor prognosis.21 One of
the hypotheses promulgated to explain increased inflam-
mation in CKD patients is the reduced clearance of cytokines
as the GFR declines.22,23 Ershler24 suggested that increased
prevalence of anemia in elderly individuals is due to
increased levels of IL-6 with age. As anemic subjects in
our study were older and had lower GFR than non-anemic
subjects, one may consider GFR and age as confounding
factors. However, our analysis suggested a potential relation-
ship between heightened levels of proinflammatory cytokines
with anemia in patients with CKD, independent of the effect
of age and renal impairment. Higher TNF-a level and the
trend for higher IL-6 and IL-8 levels (positive acute-phase
proteins) and a trend for lower serum albumin levels
(negative acute-phase protein) in anemic subjects persisted
even after sensitivity analyses for different classifications of
anemia, although, only TNF-a remained statistically sig-
nificant by all classifications for anemia. The association
between anemia and activation of proinflammatory cytokines
has been observed both in patients with cancer and in those
patients with autoimmune diseases. In a study by Maccio
et al.25, 91 ovarian cancer patients and age-matched 95
healthy controls were evaluated for relationship between
anemia and inflammatory markers. IL-6, TNF-a, CRP, and
IL-1b negatively correlated with hemoglobin levels. On
multivariate regression analysis, the stage of the disease and
the levels of IL-6 were strongly associated with lower
hemoglobin levels.25,26 Circumstantial evidence from studies
on autoimmune diseases points to inflammation related to
baselinedisease that then leads to anemia.26 Studies suggest
that inflammatory cytokines interfere with both proliferation
and differentiation of erythroid precursors by several
mechanisms, including induction of apoptosis, downregula-
tion of ESA receptors, and reduced activity and synthesis of
ESAs.27 On the other hand, states of vascular congestion and
chronic heart failures have been shown to have elevated levels
of these inflammatory markers when the renal function
declines.28–30 Whether anemia triggers these inflammatory
mediators in patients with CKD by causing subtle vascular
congestive states remains unclear. Of the inflammatory
markers, IL-6 is important by virtue of its actions not only
on cardiovascular system but also on worsening of anemia.
It induces hepcidin mRNA in hepatocytes leading to iron-
deficient erythropoiesis.31 IL-6 also has other effects on
erythropoiesis such as inhibition of the development of
burst-forming units-erythroid and colony-forming units-
erythroid in bone marrow cultures; the trend seen with CRP
levels in anemic subjects may also be important because of
the described relationships between CRP and cardiovascular
mortality.5,6,18,22,32,33 IL-10 physiologically antagonizes these
effects.34 IL-10 showed higher trend in anemic subjects
suggesting that anti-inflammatory pathways were also
affected to negate the effect of proinflammatory cytokines.
The relation between ESAs and inflammation was also
explored in our study, although the number of patients
that we studied was relatively limited. Although the anti-
apoptotic effect of ESAs on erythroid precursors in the bone
marrow is well described,35 the potential effect of ESAs on
cytokines is less well understood. Long-term administration
of ESAs has been associated with decreased levels of TNF-a
in subjects with CKD.36 Such an anti-inflammatory effect
of ESAs has been taken advantage of in treating anemia
and decreasing disease activity in rheumatoid arthritis.37
On the other hand, erythropoietin has been reported to
enhance inflammation and ischemia-induced neovasculariza-
tion by increasing the mobilization of endothelial progenitor
cells.38 Recent studies suggest a potential proinflammatory
effect for ESAs in other disease states.39 ESAs have demons-
trated vascular effects through induction of monocyte
Table 3 | Odds ratio for composite end point of IL-6 or IL-8 or TNF-a in the upper two quartiles
Parameter Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
Patients not on ESA non-anemic Reference — Reference —
1 Patients not on ESA anemic 2.3 (0.75–7.1) 0.14 1.8 (0.57–5.8) 0.30
2 Patients on ESAs 10.5 (1.3–85.4) 0.02* 9.1 (1.12–75.3) 0.03*
3 Age 1.01 (0.99–1.04) 0.21 1.01 (0.98–1.05) 0.41
4 Male gender 1.75 (0.68–4.5) 0.24 1.4 (0.38–5.39) 0.79
5 Diabetes 1.04 (0.39–2.7) 0.93 0.62 (0.17–2.2) 0.47
6 Hypertension 0.98 (0.31–3.0) 0.98 0.51 (0.11–2.3) 0.39
6 Hemoglobino11 g/100 ml 6.1 (0.76–48.9) 0.08 2.2 (0.20–23.9) 0.50
7 GFR 0.98 (0.97–1.00) 0.11 0.99 (0.97–1.01) 0.35
8 Albumin 0.61 (0.19–1.8) 0.39 0.68 (0.20–2.28) 0.53
9 Ferritin 1.0 (0.99–1.1) 0.95 0.99 (0.99–1.00) 0.98
10 Platelets 0.99 (0.99–1.00) 0.68 1.00 (0.99–1.01) 0.36
CI, confidence interval; ESAs, erythropoiesis-stimulating agents; GFR, glomerular filtration rate; IL, interleukin; OR, odds ratio.
Multivariate logistic regression was done by step-wise backward elimination by log-likelihood ratio (LR) and confirmed by forward LR.
*Po0.05.
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chemoattractant protein-1, which enhances atherogenicity.40,41
Furthermore, ESAs activate vascular smooth muscle cells,
endothelium, and platelets enhancing thrombogenity and loss
of vasodilatory potential.40–44 In another study, when 1270
subjects aged 65 years or older were evaluated, the number of
elevated inflammatory markers (CRP, IL-6, IL-1b, and TNF-a)
was associated with progressively higher levels of erythropoie-
tin levels in non-anemic non-CKD participants, independent
of age, sex, and hemoglobin. Out of these inflammatory
markers, IL-6 had a very strong association.45 Although the
pro- and anti-inflammatory roles of ESAs are inconclusive, the
responsiveness of the erythroid progenitors to ESAs is blunted
in inflamed severe chronic disease patients due to inflamma-
tory cytokines interfering with the ESA–receptor signal
transduction pathways.46 As hemoglobin levels are inversely
correlated with these cytokines, one would expect reduced
levels of these cytokines with the use of ESAs, as ESA therapy
increases hemoglobin levels. However, in our study, the use
of ESAs was associated with increased OR for the upper two
quartiles of IL-6, IL-8, and TNF-a and the upper tertile for
CRP levels. The mechanism for ESA-associated increase in
cytokine levels is not clear. One possibility is that of
confounding by indication, that is, severely inflamed patients
were more severely anemic and therefore required ESA
therapy. An alternative hypothesis is that induction of
proinflammatory cytokines by ESAs occurs as a consequence
of ESAs acting via erythropoetin receptors on macrophages
(or other cell types expressing these cytokines), which on
activation secrete IL-6, IL-8, and TNF-a. If increased synthesis
of these cytokines is demonstrated to result from ESA
treatment, this could be important as these cytokines
are major acute-phase reactant proteins and markers of
the malnutrition–inflammation–cachexia syndrome. Indeed,
heightened IL-6, IL-8, and TNF-a levels have been associated
with an increased risk of death in the dialysis population.47,48
Furthermore, this could be one explanation for the observa-
tion of increased risk for all-cause and cardiovascular mortality
in patients targeted to higher hemoglobin levels with higher
doses of ESAs.2,3,49 In our study, we also observed that IL-10
was not significantly elevated in subjects on ESAs, perhaps
suggesting that inflammation counter-regulatory mechanisms
were not significantly triggered in patients on ESAs.
Our study had several strengths. To our knowledge, this
study is the first to describe the association and interaction of
ESAs, anemia, and inflammatory cytokines in the setting of
CKD. Although our study does not indicate causality, we
believe that, conceptually, it is hypothesis-generating. Our
study evaluated different definitions of anemia, thus enhan-
cing its internal validity. Finally, the assays were performed
using defined validated techniques with limited intra-assay
variability. An important limitation to this study is its
observational design and that we studied prevalent patients.
The effect of unmeasured confounders should limit infer-
ences regarding causality. The issue of confounding by
indication also requires us to be cautious in the interpreta-
tion of the data; indeed, our observation on associations
between proinflammatory cytokines and anemia and ESAs
requires further exploration and confirmation by longi-
tudinal prospective studies.
In summary, our data suggest an association between
anemia and increased levels of the proinflammatory cytokine
TNF-a. We also observed an association between higher
levels of proinflammatory cytokines and ESA treatment in
our anemic patients, raising a possible explanation for why
ESA therapy may be associated with adverse effects under
certain circumstances.
PATIENTS AND METHODS
The Brigham CKD cohort is a prospective observational
cohort established in 2004 that is designed to study the influ-
ence of specific modifiable factors on the risk of progression
of CKD and the risk of CVD in patients with CKD. Inclusion
criteria include patients aged X18 years and CKD defined
as GFR o60 ml/min per 1.73 m2 or GFRX 60 ml/min
per 1.73 m2 with albuminuria. eGFR was calculated by the
Modification of Diet in Renal Disease II equation (eGFR
(ml/min per 1.73 m2)¼ 186 [Cr (mg/100 ml)]1.154
(age)0.203 (1.21 if subject is black)). Exclusion criteria
included unwillingness to provide informed consent, patients
who were hospitalized or had a thrombotic event or
cardiovascular event 1 month prior to enrollment, institu-
tionalized subjects (nursing home resident, skilled nursing
facility resident, prisoner), those with a life expectancy p3
years, known human immunodeficiency virus patient, an
active malignant neoplastic disease other than localized non-
melanoma skin cancer, patients on immunotherapy or
immunosuppressive treatment for a primary or secondary
renal disease, a previous diagnosis of multiple myeloma,
and those patients enrolled in an intervention study. One
hundred patients out of 142 who had blood samples were
included for the analysis. The study was approved by the
institutional review board at Partners Healthcare and an
informed consent was taken from each patient. Anemia was
defined as Hgbo12 g/dl in women and Hgbo13 g/dl in men
on treatment with ESAs; modification of WHO criteria. For
testing our analysis, which tests the effect of ESAs on
inflammation in anemia, the WHO definition for anemia was
used. Treatment with ESAs and the dose utilized were
ascertained by review of the longitudinal medical record,
direct contact with the patient, and reviewing the pharmacy
record.
Biochemical analysis
Plasma was stored at 801C until analysis. The multiplex
human CVDs biomarkers panels 1 and 3 were used (HCVD1-
67AK-4Plex, HCVD3-67CK-6Plex; Linco Inc. (Millipore
corporation, Chicago, IL, USA) part of Millipore, MA,
USA) for the simultaneous quantification of the several
analytes. Of these, inflammatory markers include IL-1b, IL-6,
IL-8, TNF-a, and IL-10. All examined analytes were tested
individually and in combination to ensure that there were
no crossreactions. All measurements were performed in
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duplicate and the investigators were blinded to clinical
characteristics of the patients being studied. Briefly, the
multibiomarker and cytokine standards were resuspended in
provided assay buffer and then differently serially diluted. A
total of 25 ml of reconstituted standard, Quality Controls, or
sample (HCVD-1 required a 1:50 serum dilution) was added
to each well of a 96-well plate with 25 ml of the bead
suspension. The plate was sealed, covered with aluminum
foil, and incubated overnight (16–18 h) with agitation on a
plate shaker at 41C. Then the plate was washed twice with
200 ml/well of wash buffer, removing buffer by vacuum
filtration (o100 mm Hg) between each wash. This was
followed by addition of 25 ml of a detection antibody cocktail
into each well and incubation at room temperature for
60 min. A total of 25 ml of a streptavidin–phycoerythrin
solution was added to each well and incubated at room
temperature for 30 min. The plate was then analyzed on the
Luminex IS100 analyzer (Luminex Inc., Austin, TX, USA).
The data were saved and evaluated as median fluorescence
intensity using appropriate curve-fitting software (Luminex
100IS software version 2.3). A five-parameter logistic method
with weighting was used.
C-reactive protein in blood was determined by a highly
sensitive latex-based immunoassay (Dade Behring, Newark,
DE, USA) in collaboration with Paul Ridker/Nader Rifai
laboratories at the Children’s hospital, Harvard Medical
School, Boston. The concentration of CRP was determined
using an immunoturbidimetric assay on the Hitachi 917
analyzer (Roche Diagnostics, Indianapolis, IN, USA), using
reagents and calibrators from DiaSorin (Stillwater, MN,
USA). In this assay, an antigen–antibody reaction occurs
between CRP in the sample and an anti-CRP antibody that
has been sensitized to latex particles, and agglutination
results. This antigen–antibody complex causes an increase in
light scattering, which is detected spectrophotometrically,
with the magnitude of the change being proportional to the
concentration of CRP in the sample. This assay has a
sensitivity of 0.03 mg/l. The day-to-day variabilities of the
assay at concentrations of 0.91, 3.07, and 13.38 mg/l are 2.81,
1.61, and 1.1%, respectively. This method has been shown
efficacious in predicting risk of recurrent coronary events.33
Statistical analysis
Continuous data were analyzed with independent sample
t-test, and categorical data were analyzed with w2 statistic in
the analysis of demographic characteristics. The levels of IL-6,
IL-8, TNF-a, IL-10, serum ferritin, albumin, and highly
sensitive CRP levels deviated from normal distribution and
hence we used Wilcoxon rank-sum test (also called
Mann–Whitney U test) to compare anemic and non-anemic
subjects and subjects treated with ESAs and epo-naive.
Spearman’s correlation coefficients were calculated for pairs
of continuous variables. Logistic regression was used to
calculate OR for reaching a composite end point of upper
two quartiles (third and fourth quartile vs first and second
quartiles) of IL-6 or IL-8 or TNF-a. Mantel–Haenszel linear
by linear association was used to assess the inflammatory
markers in tertiles or quartiles. Bar diagrams were used to
represent upper two and lower two quartiles of TNF-a, IL-6,
IL-8, albumin, and ferritin, and unadjusted OR were
calculated for the effect of ESAs. SPSS version 15 (SPSS
Inc., Chicago, IL, USA) was used to analyze the data.
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